Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis

• Published in: International journal for quality in health care Vol. 35; no. 2
• Main Authors: Huang, Xiaoting, Liu, Yiwei, Lin, Shen, Wang, Hang, Deng, Yujie, Rao, Xin, Guo, Xianzhong, Jiang, Xinchan, Weng, Xiuhua, Huang, Pinfang
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 15.04.2023
• Subjects: Aromatase Inhibitors - therapeutic use; Breast Neoplasms - drug therapy; China; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Female; Humans; Postmenopause - drug effects; Quality-Adjusted Life Years; Zoledronic Acid - therapeutic use; China; early breast cancer; cost-effectiveness; bone metastasis; postmenopausal women; zoledronic acid

Abstract Combination therapy of zoledronic acid (ZOL) plus aromatase inhibitor (AI) was found to reduce bone metastasis risk and improve overall survival for treatment-naïve postmenopausal women (PMW) with hormone receptor–positive (HR+) early breast cancer (EBC), when compared with AI alone. The ob...